Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TV005 (Merck & Co.)
- Development stage
- Unknown
- Lead developer
- Instituto Butantan
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
TV005 is a live attenuated tetravalent dengue vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID). It is designed to provide protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). The vaccine is a mixture of four recombinant live attenuated dengue virus strains: rDEN1Δ30, rDEN2/4Δ30 (a chimeric strain), rDEN3Δ30/31, and rDEN4Δ30. Attenuation is achieved through specific deletions in the 3′ untranslated region of the viral genome and structural gene chimerization. It is typically administered as a single subcutaneous dose and has shown high levels of immunogenicity and safety in clinical trials, including Phase II trials in Bangladesh and Phase III trials in Brazil.
- Other names
- TetraVax-DVNIAID dengue vaccine
02
Targets
DENV-4 (Dengue virus serotype 4)DENV-1 (Dengue virus serotype 1)DENV-3 (Dengue virus serotype 3)DENV-2 (Dengue virus serotype 2)
Beyond the preview
Go deeper on TV005 (Merck & Co.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TV005 (Merck & Co.).